The value of nerve ultrasound in patients with neurofibromatosis type 1

The value of nerve ultrasound in patients with neurofibromatosis type 1 - Nerve ultrasound in neurofibromatosis type 1

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48220

Enrollment

Registered

2019-04-08

Start date

2019-07-11

Completion date

Unknown

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurofibromatosis type 1 Von Recklinghausen's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >=18 years - Diagnosed with neurofibromatosis type 1 - Treatment at the outpatient clinic of the Erasmus MC Cancer Institute (Rotterdam)

Exclusion criteria

Exclusion criteria: - comorbidity associated with (poly)neuropathy (e.g. alcoholism, diabetes mellitus) - comorbidity mimicking neuropathic complaints (e.g. myelopathy) - inability to give informed consent or to undergo HRUS

Design outcomes

Primary

Measure	Time frame
The main study parameters are the number of HRUS abnormalities and their characteristics (cross-sectional area, presence of vascularization) and the presence or absence of neurological deficits.	—

Secondary

Measure	Time frame
Secondary study parameters are: - the number of newly detected nerve abnormalities with HRUS after two years of follow-up; - the increase in CSA and/or vascularization of nerve abnormalities detected with HRUS after two years of follow-up.	—

Countries

Netherlands

Outcome results